Niaspan and Statin vs. Other Lipid-Modifying Therapies for Dyslipidemia

This study is about comparing the effectiveness of different treatments for dyslipidemia, a condition where there are high levels of cholesterol or fats in the blood. The treatments being compared include a combination of Niaspan and atorvastatin, a combination of simvastatin and ezetimibe, rosuvastatin alone, and a combination of Niaspan and rosuvastatin. The goal is to see which of these treatments works best for managing dyslipidemia. This study is important for adults aged 21 years and older who are eligible for treatment based on the National Cholesterol Education Program Adult Treatment Panel III recommendations and have triglycerides levels less than or equal to 300 mg/dL. The results of this study could help improve care for people with dyslipidemia by identifying the most effective treatment options. During this 12-week study, participants are randomly assigned to one of four treatment groups. In the first group, participants receive a combination of Niaspan and atorvastatin, with the doses adjusted to 2000 mg and 40 mg, respectively. The second group receives a combination of simvastatin, adjusted to 40 mg, and ezetimibe, maintained at 10 mg. The third group receives rosuvastatin alone, with the dose adjusted to 40 mg. The fourth group receives a combination of Niaspan and rosuvastatin, with the doses adjusted to 1000 mg and 20 mg, respectively. The study measures the change in LDL-C (low-density lipoprotein cholesterol, also known as 'bad' cholesterol) from the start to the end of the study to evaluate the effectiveness of each treatment.